| Gene symbol | CD70 | Synonyms | CD27-L, CD27L, CD27LG, LPFS3, TNFSF7, TNLG8A | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19p13.3 | dbXrefs | |
| Description | CD70 molecule | ||||
| GTO ID | GTC3935 |
| Trial ID | NCT06492304 |
| Disease | T Cell Lymphoma | B Cell Lymphoma | Acute Myeloid Leukemia |
| Altered gene | CD70 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CTX131 |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies |
| Year | 2024 |
| Country | United States |
| Company sponsor | CRISPR Therapeutics |
| Other ID(s) | CRSP-ONC-008 |
| Cohort 1 | |||||||||||
|
|||||||||||